Highlights BioAtla, Inc.

Equities

BCAB

US09077B1044

Real-time Estimate Cboe BZX Other stock markets 02:52:17 2024-04-29 pm EDT			5-day change	1st Jan Change
2.61 ^USD	+2.76%		+19.27%	+5.69%

Mar. 27	HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	MT
Mar. 26	Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 26	CI
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	CI
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	CI
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Viatris Projects Lower 2023 Revenue Despite Swinging to Fourth-Quarter Profit	23-02-27	MT
BioAtla Says US FDA Approves Investigational New Drug Application for BA3182 to Treat Adenocarcinoma	23-02-23	MT
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3182, A Cab Epcamxcab-Cd3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma	23-02-23	CI
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
BioAtla : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)	22-08-09	PU
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
BIOATLA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-05	AQ
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
BioAtla : Presentation_Needham_FINAL91 - Read-Only.pdf	22-04-11	PU
BIOATLA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	22-02-28	AQ
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
BioAtla : JPM Presentation 2022.pdf	22-01-11	PU
BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments	22-01-10	MT
Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investigate Bioatla's Two Lead CAB-ADC Candidates, BA3011 and BA3021, in Combination with Bristol Myers Squibb's Anti-PD-1 Therapy Opdivo	22-01-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioAtla, Inc.

Equities

BCAB

US09077B1044

Highlights

Filters